Related Experiment Video
Updated: May 23, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Challenges in non-muscle invasive bladder cancer: lessons from a regional review
Mark T Siddins1, Vun Vun Wong, Jude Thomas Fitzgerald
1School of Medicine, Faculty of Health Sciences, Flinders University, Bedford Park, South Australia, Australia. siddinsmark@hotmail.com
Background:
Surveillance programmes for bladder cancer are invasive and expensive. Existing guidelines are complex, and the capacity to implement these is untested. The present study examined treatment consistency, and ease of guideline implementation, for patients undergoing surveillance of non-muscle invasive bladder cancer.
Method:
Eligible cancers treated between 1 January 2005 and 30 June 2009 were identified from a prospective database in a regional South Australian Urology service. Each was analysed with respect to the timing of cystoscopic surveillance and the use of intraoperative chemotherapy. For high-risk patients, the use of urine cytology, upper tract imaging, adjuvant therapy and re-resection of T1 cancers was reviewed.
Results:
Eight hundred and nineteen cystoscopies were performed in the surveillance of 313 cancers in 193 patients. Within each risk category, the pattern of cystoscopic surveillance varied widely. In high-risk patients, the use of cytology, upper tract imaging, adjuvant therapy and re-resection was infrequent (3-56%). An attempt was made to standardize management through the implementation of guidelines. No overall practice improvement was observed after 18 months. Difficulty incorporating new algorithms into practice and ensuring a consistent longitudinal focus in care were felt contributory. Of 78 low-risk cancer patients, 55% underwent more cystoscopies than would have been expected. In 235 cancer patients at high or intermediate risk, 43% received less follow-up than would have been recommended.
Conclusion:
Surveillance patterns were inconsistent across all risk categories. The development of consensus recommendations did not significantly alter clinical practice. Implementation of clinical guidelines for this important disease represents a significant challenge in acute hospital settings.
Insights
Bladder cancer surveillance is complex and inconsistent, even after guideline implementation. Improving clinical practice for non-muscle invasive bladder cancer remains a significant challenge in hospitals.
Area of Science:
- Urology
- Oncology
- Clinical Practice Guidelines
Background:
- Bladder cancer surveillance is invasive and costly.
- Current guidelines for non-muscle invasive bladder cancer (NMIBC) are complex and their implementation is untested.
- Assessing treatment consistency and guideline implementation is crucial for effective NMIBC management.
Purpose of the Study:
- To examine treatment consistency in bladder cancer surveillance.
- To evaluate the ease of implementing clinical guidelines for NMIBC.
- To analyze surveillance patterns and adherence to recommendations across different risk categories.
Main Methods:
- Analysis of a prospective database of NMIBC cases treated between 2005 and 2009.
- Review of cystoscopic surveillance timing and intraoperative chemotherapy use.
- Assessment of adherence to guidelines for high-risk patients, including urine cytology, upper tract imaging, adjuvant therapy, and re-resection.
Main Results:
- Wide variation in cystoscopic surveillance patterns observed across all risk categories.
- Infrequent use of recommended procedures (3-56%) for high-risk patients.
- No significant practice improvement noted after 18 months of guideline implementation; challenges included algorithm integration and consistent care focus.
Conclusions:
- Bladder cancer surveillance patterns are inconsistent, regardless of risk stratification.
- Development of consensus recommendations did not substantially change clinical practice.
- Implementing clinical guidelines for NMIBC presents significant challenges in acute care settings.
